

REVIEW

Open Access



# Pathophysiology and clinical implications of the veno-arterial PCO<sub>2</sub> gap

Zied Ltaief<sup>1</sup>, Antoine Guillaume Schneider<sup>1\*</sup> and Lucas Liaudet<sup>1,2</sup>

## Abstract

This article is one of ten reviews selected from the Annual Update in Intensive Care and Emergency Medicine 2021. Other selected articles can be found online at <https://www.biomedcentral.com/collections/annualupdate2021>. Further information about the Annual Update in Intensive Care and Emergency Medicine is available from <https://link.springer.com/bookseries/8901>.

## Introduction

The persisting high mortality of circulatory shock highlights the need to search for sensitive early biomarkers to assess tissue perfusion and cellular oxygenation, which could provide important prognostic information and help guide resuscitation efforts. Although blood lactate and venous oxygen saturation (SvO<sub>2</sub>) are commonly used in this perspective, their usefulness remains hampered by several limitations. The veno-arterial difference in the partial pressure of carbon dioxide (Pv-aCO<sub>2</sub> gap) has been increasingly recognized as a reliable tool to evaluate tissue perfusion and as a marker of poor outcome during circulatory shock, and it should therefore be part of an integrated clinical evaluation. In this chapter, we present the physiological and pathophysiological determinants of the Pv-aCO<sub>2</sub> gap and review its implications in the clinical assessment of circulatory shock.

## Physiological aspects of CO<sub>2</sub> production and transport

Under aerobic conditions, CO<sub>2</sub> is produced at the mitochondrial level as a by-product of substrate oxidation (pyruvate and citric acid cycle intermediates) (Fig. 1). The relationship between the amount of oxygen consumed


(VO<sub>2</sub>) and CO<sub>2</sub> produced (VCO<sub>2</sub>) during aerobic metabolism is termed the respiratory quotient (RQ = VCO<sub>2</sub>/VO<sub>2</sub>), and differs according to the main type of oxidized substrate (glucose, RQ = 1; proteins, RQ = 0.8; lipids, RQ = 0.7). Under anaerobic conditions, protons (H<sup>+</sup>) resulting from lactic acid production and ATP hydrolysis may generate CO<sub>2</sub> following buffering by bicarbonates (HCO<sub>3</sub><sup>-</sup>), leading to the formation of so-called “anaerobic CO<sub>2</sub>” [1]. Once formed, CO<sub>2</sub> diffuses within the surrounding environment and capillary blood, to be transported to the lungs for elimination. In blood, CO<sub>2</sub> transport is partitioned into three distinct fractions [2]:

1. Dissolved CO<sub>2</sub> fraction, which is in equilibrium with the partial pressure of CO<sub>2</sub> (PCO<sub>2</sub>), according to Henry's law of gas solubility:  $V_{\text{gas}} = S_{\text{gas}} \times (P_{\text{gas}}/P_{\text{atm}})$ , where  $V_{\text{gas}}$  is the volume of dissolved gas (in ml/ml),  $S_{\text{gas}}$  is the Henry's constant of gas solubility (0.52 ml/ml for CO<sub>2</sub> at 37 °C), and  $P_{\text{atm}}$  the atmospheric pressure. Thus, in arterial blood with a PaCO<sub>2</sub> of 40 mmHg (at sea level, 37 °C), dissolved CO<sub>2</sub> =  $[0.52 \times (40/760)] = 27$  ml/l, which is about 5% of the total CO<sub>2</sub> (note that, in mmol/l, Henry's constant for CO<sub>2</sub> = 0.03 mmol/l/mmHg; also note that the conversion factor from mmol to ml CO<sub>2</sub> is ~ 22.3).
2. Bicarbonate (HCO<sub>3</sub><sup>-</sup>). CO<sub>2</sub> in blood readily diffuses within red blood cells (RBCs), where it combines with H<sub>2</sub>O to form carbonic acid (H<sub>2</sub>CO<sub>3</sub>), a reac-

\*Correspondence: Antoine.Schneider@chuv.ch

<sup>1</sup> Service of Adult Intensive Care Medicine, Lausanne University Hospital, 1011 Lausanne, Switzerland

Full list of author information is available at the end of the article



tion catalyzed by the enzyme carbonic anhydrase. In turn, H<sub>2</sub>CO<sub>3</sub> dissociates to form HCO<sub>3</sub><sup>-</sup> and H<sup>+</sup>. While H<sup>+</sup> is buffered by hemoglobin (formation of HbH), HCO<sub>3</sub><sup>-</sup> exits the RBC in exchange for a chloride anion (Cl<sup>-</sup>) via a HCO<sub>3</sub><sup>-</sup>-Cl<sup>-</sup> transporter (erythrocyte chloride shift or Hamburger effect). Thus, the HCO<sub>3</sub><sup>-</sup> concentration increases in venous blood whereas the Cl<sup>-</sup> concentration diminishes. CO<sub>2</sub> transport as HCO<sub>3</sub><sup>-</sup> (RBC and plasma fraction) represents about 90% of the total CO<sub>2</sub> content in arterial blood (this proportion is lower in venous blood due to the Haldane effect). Taking into account a normal hematocrit of 0.45, the CO<sub>2</sub> content under the form of HCO<sub>3</sub><sup>-</sup> (in whole blood) is ~435 ml/l.

3. Formation of carbamino compounds within hemoglobin: part of the CO<sub>2</sub> within the RBC combines with free amino (R-NH<sub>2</sub>) groups within hemoglobin to form carbamino-hemoglobin (R-NH<sub>2</sub>-CO<sub>2</sub>). This reaction is enhanced when hemoglobin carries less oxygen, implying that more CO<sub>2</sub> is transported as (R-NH<sub>2</sub>-CO<sub>2</sub>) when the PO<sub>2</sub> decreases, which is the basis of the Haldane effect described below. CO<sub>2</sub> transport under the form of (R-NH<sub>2</sub>-CO<sub>2</sub>) represents about 5% of the total CO<sub>2</sub> content in arterial blood (~1.1 mmol/L ≈ 25 ml/l).

In summary, the total CO<sub>2</sub> content of blood under physiological conditions equals:


$$[\text{Dissolved CO}_2] + [\text{HCO}_3^-] + [\text{R-NH}_2-\text{CO}_2]$$

which is ≈490 ml/l in arterial blood and ≈535 ml/l in mixed venous blood, hence a veno-arterial difference of approximately 45 ml/l. A more precise calculation of the CO<sub>2</sub> content of blood can be obtained by the Douglas equation, but this is too complex to be calculated at the bedside [3].

#### The CO<sub>2</sub> dissociation curve (PCO<sub>2</sub>-CCO<sub>2</sub> relationship)

As is the case for oxygen, a relationship exists between the PCO<sub>2</sub> and the CO<sub>2</sub> content (CCO<sub>2</sub>) of blood (Fig. 2). However, in contrast to the sigmoid shape of the O<sub>2</sub> dissociation curve, the CO<sub>2</sub> dissociation curve is slightly curvilinear, indicating a proportional increase in CCO<sub>2</sub> over a wide range of PCO<sub>2</sub>. In the physiological range, the relationship between CCO<sub>2</sub> and PCO<sub>2</sub> can therefore be resolved by the equation:

$$\text{PCO}_2 = k \times \text{CCO}_2 \quad (1)$$



Important information provided by the PCO<sub>2</sub>-CCO<sub>2</sub> relationship is the shift produced at different values of oxygen saturation of hemoglobin (HbO<sub>2</sub>). Indeed, as hemoglobin gets saturated with O<sub>2</sub>, it can carry less CO<sub>2</sub> as carbaminoHb, and inversely. This behavior is known as the Haldane effect, which implies that for a same PCO<sub>2</sub>, CCO<sub>2</sub> is higher at lower HbO<sub>2</sub> saturation. In other words, this means that as the  $k$  constant in the relationship above decreases, the PCO<sub>2</sub>-CCO<sub>2</sub> curve is shifted to the left. The consequence of this effect is that, in tissues, more CO<sub>2</sub> is loaded by Hb as it releases O<sub>2</sub>, allowing PCO<sub>2</sub> to increase only moderately (from 40 to 46 mmHg), in spite of a marked increase in CCO<sub>2</sub> due to the tissue production of CO<sub>2</sub>. Without the Haldane effect, the venous PCO<sub>2</sub> would increase significantly more for a similar increase in CO<sub>2</sub> content.

The curvilinearity of the CO<sub>2</sub> dissociation curve indicates that CCO<sub>2</sub> increases more steeply at low values of PCO<sub>2</sub> and is more flat at high PCO<sub>2</sub> values. It is also noticeable that the curve can be displaced by a certain number of factors: In conditions of metabolic acidosis, the reduction in HCO<sub>3</sub><sup>-</sup> due to H<sup>+</sup> buffering reduces the formation of carbamino (R-NH<sub>2</sub>-CO<sub>2</sub>) compounds inside hemoglobin [4]. As a result, for a given CCO<sub>2</sub>, the PCO<sub>2</sub> must increase, which means an increase in the  $k$

constant, and a rightward shift of the relationship. The opposite occurs under conditions of metabolic alkalosis. Other factors influencing the curve are the hematocrit and temperature. At increasing hematocrit, there is a decrease in plasma space with a reduction of HCO<sub>3</sub><sup>-</sup> and a decrease in CO<sub>2</sub> content at any value of PCO<sub>2</sub>, with a shift to the right of the curve. At increasing temperatures, the reduced CO<sub>2</sub> solubility also shifts the relationship to the right [4]. These considerations imply, therefore, that PvCO<sub>2</sub> may vary at constant total venous CCO<sub>2</sub> according to the particular conditions (HbO<sub>2</sub> saturation [i.e., the Haldane effect], arterial pH, temperature and hematocrit).

### The Pv-aCO<sub>2</sub> gap: pathophysiology and clinical implications

As discussed earlier, the CCO<sub>2</sub> in the venous side of the circulation is determined by the aerobic production of CO<sub>2</sub> in tissues, influenced by the metabolic rate and the respiratory quotient, and may also increase via non-aerobic production of CO<sub>2</sub>. The generation of CO<sub>2</sub> de facto increases the CCO<sub>2</sub> on the venous side of the circulation, implying an obligatory difference between arterial and venous CCO<sub>2</sub>, termed the veno-arterial

difference in  $CCO_2$ , or veno-arterial  $CCO_2$  gap:  $va-CCO_2$  gap = (venous - arterial)  $CCO_2$  [1].

The tissue  $VCO_2$  does not accumulate under normal conditions, being washed out by the blood flowing across the tissue and eliminated by the lungs. Accordingly, any reduction in tissue blood flow (stagnant condition) will result in an accumulation of tissue  $CO_2$ , implying an increase in the  $va-CCO_2$  gap, in accordance with Fick's principle:

$$VCO_{2\text{tissue}} = [(\text{Blood flow}_{\text{tissue}} \times (va - CCO_2 \text{ gap}_{\text{tissue}}))] ]$$

At the systemic level, the relationship is:

$$VCO_2 = [(\text{Cardiac output} \times (va - CCO_2 \text{ gap}))]$$

According to the equation ( $PCO_2 = k \times CCO_2$ ), the Fick equation for  $CO_2$  can be rewritten as:

$$k \times VCO_2 = [\text{Cardiac output} \times (Pv - PaCO_2)]$$


and

$$(Pv - PaCO_2) = [(k \times VCO_2) / \text{Cardiac output}]$$

Therefore, the  $Pv-aCO_2$  gap represents a very good surrogate indicator of the adequacy of cardiac output and tissue perfusion under a given condition of  $CO_2$  production. The normal  $Pv-aCO_2$  gap is comprised between 2 and 6 mmHg [5], and many studies assessing  $Pv-aCO_2$  gap in clinical conditions used a cut-off value of 6 mmHg above which the gap is considered abnormally elevated. Although the venous  $PCO_2$  should ideally be obtained in a mixed venous blood sampling, good agreement between central and mixed venous  $PCO_2$  values has been reported [6]. Therefore, both central and mixed venous  $PCO_2$  can be used for the calculation of the  $va-CO_2$  gap, as long as the variables are not interchanged during treatment in a given patient.

#### The inverse relationship between cardiac output and the $Pv-aCO_2$ gap

The inverse relationship between cardiac output and the  $Pv-aCO_2$  gap (Fig. 3) has been repeatedly demonstrated in both experimental [7] and clinical [8] settings. It is noteworthy that this relationship is not linear, but curvilinear (Fig. 3). At very low cardiac output, the ( $Pv-aCO_2$  gap) indeed increases more rapidly. This large increase in  $Pv-aCO_2$  gap is primarily due to the flattened relation between  $CCO_2$  and  $PCO_2$  at high values of  $CCO_2$  in conditions of tissue hypercarbia [5], and this is further magnified if tissue metabolic acidosis develops, due to the rightward shift of the  $PCO_2-CCO_2$  relationship in acidic conditions (increased  $k$  coefficient, see above). Also, venous accumulation of  $CO_2$  will increase as a consequence of low pulmonary perfusion and  $CO_2$  elimination,



**Fig. 3** The inverse relationship between cardiac output and the  $Pv-aCO_2$  gap. A reduction in cardiac output is associated with a progressive increase in the  $Pv-aCO_2$  gap, which becomes exponential at very low cardiac output values, because of the flat slope of the  $CO_2$  dissociation curve in conditions of tissue hypercarbia. The relationship is displaced to the right at higher  $CO_2$  production ( $VCO_2$ )

further widening the gap [9]. In contrast, the increase in  $Pv-aCO_2$  in very low flow states with conditions of  $VO_2$ -oxygen delivery ( $DO_2$ ) dependence will be attenuated by the mandatory reduction in aerobic  $VCO_2$ . Such a decrease in  $VCO_2$  results in a leftward shift of the cardiac output/ $Pv-aCO_2$  gap relationship, as shown in Fig. 3 [5].

#### $Pv-aCO_2$ gap and tissue dysoxia

In addition to tracking changes in cardiac output and tissue perfusion, the  $Pv-aCO_2$  gap can increase through an augmentation of  $VCO_2$  [8]. Under aerobic conditions, that is in the absence of any clinical sign of shock or increased blood lactate, such an increase reflects an increased metabolic demand or an increase in RQ (glucidic diet), or both. Physiologically, an increased metabolic rate is generally coupled with an increase in cardiac output, but such adaptation may not occur in critically ill patients with inadequate cardiovascular reserves, which may result in an increased  $Pv-aCO_2$  gap. Interventions should here be targeted first to reduce the metabolic demand. Persistence of an increased  $Pv-aCO_2$  gap should not necessarily prompt therapies to increase cardiac output, given the risk associated with deliberate increase in cardiac output in the absence of tissue dysoxia [10]. However, it is noteworthy that an increased  $Pv-aCO_2$  gap immediately after surgery in high risk patients, independent of their hemodynamic condition,  $SvO_2$  and lactate, has been associated with significantly more complications [11]. This suggests that a high  $Pv-aCO_2$  gap could track insufficient resuscitation and might represent a goal

for hemodynamic optimization in such patients, but this issue is controversial and remains to be proven [9].

Under *anaerobic* conditions, the question as to whether the Pv-aCO<sub>2</sub> gap can be used as a marker of tissue dysoxia, by detecting increased anaerobic VCO<sub>2</sub> from H<sup>+</sup> buffering, has attracted much attention. An advantage of Pv-aCO<sub>2</sub> gap in this sense would be its ability to rapidly track changes in CO<sub>2</sub> formation, hence providing sensitive, rapid and continuous detection of ongoing anaerobiosis. This would contrast from usual markers of tissue dysoxia, such as SvO<sub>2</sub> or lactate. Indeed, SvO<sub>2</sub> can be unreliable in conditions of reduced oxygen extraction and hyperdynamic circulation (sepsis) [12]. The disadvantage of lactate is its lack of specificity as a marker of dysoxia (type A vs type B hyperlactatemia), and its relatively slow clearance kinetics dependent on liver perfusion and function [13], which limits its utility to rapidly track changes in tissue oxygenation [9].

#### **The Pv-aCO<sub>2</sub> gap in stagnant dysoxia**

In essence, tissue dysoxia is classically attributed to stagnant, hypoxic, anemic and cytopathic mechanisms. As a sensitive marker of reduced cardiac output, an increased Pv-aCO<sub>2</sub> gap is a reliable indicator of stagnant dysoxia. Importantly, the major gap noted under very low flow conditions (see earlier) has been associated with a global reduction in VCO<sub>2</sub> (VO<sub>2</sub>-DO<sub>2</sub> dependence), implying that any increase in anaerobic VCO<sub>2</sub> could not offset the depressed aerobic VCO<sub>2</sub> [7]. Therefore, the increased Pv-aCO<sub>2</sub> gap depends entirely on the stagnant accumulation of tissue CO<sub>2</sub>, but not on increased anaerobic VCO<sub>2</sub> in low flow conditions [1, 14].

#### **The Pv-aCO<sub>2</sub> gap in hypoxic or anemic dysoxia**

To address the role of the Pv-aCO<sub>2</sub> gap to detect hypoxic dysoxia, Vallet et al. reduced DO<sub>2</sub> below the critical threshold in an isolated dog hindlimb model, by reducing blood flow or by decreasing PO<sub>2</sub> [15]. Both conditions similarly reduced VO<sub>2</sub> and O<sub>2</sub> extraction, but the Pv-aCO<sub>2</sub> gap increased exclusively in the ischemic, but not hypoxic condition, implying that stagnant, but not hypoxic dysoxia was the responsible mechanism [15]. Comparable results were obtained by Nevière et al. in the intestinal mucosa of pigs, following the systemic reduction in DO<sub>2</sub> to similar levels either by reduction of cardiac output or arterial PO<sub>2</sub> [16]. With respect to anemic dysoxia, similar conclusions were obtained in sheep hemorrhage models, in which no increase in Pv-aCO<sub>2</sub> gap was detected under conditions of VO<sub>2</sub>/DO<sub>2</sub> dependency due to reduced hemoglobin concentration [17], unless there was a concomitant reduction in cardiac output [18].

Hence, significant hypoxic or anemic dysoxia occurs in the absence of any Pv-aCO<sub>2</sub> gap increase.

#### **The Pv-aCO<sub>2</sub> gap in cytopathic dysoxia**

An acquired intrinsic abnormality of tissue O<sub>2</sub> extraction and cellular O<sub>2</sub> utilization, primarily related to mitochondrial impairment, defines the concept of cytopathic hypoxia, and the resulting cellular bioenergetic failure could represent an important mechanism of organ dysfunction in sepsis [19]. Mitochondrial defects have been demonstrated in several tissues obtained from animals in various models of sepsis, and limited data also exist on altered mitochondrial metabolism in human biopsy samples or circulating blood cells [20]. The detection of cytopathic hypoxia, however, is still not feasible at the bedside, although new techniques such as the measurement of mitochondrial O<sub>2</sub> tension using protoporphyrin IX-Triplet State Lifetime Technique (PpIX-TSLT) are currently being developed [21]. Furthermore, impaired O<sub>2</sub> extraction in sepsis does not necessarily imply cytopathic hypoxia, as it may be related to impaired microcirculation.

Theoretically, the increased anaerobic CO<sub>2</sub> generation in conditions of cytopathic hypoxia could result in increased anaerobic VCO<sub>2</sub> leading to an increased Pv-aCO<sub>2</sub> gap. This assumption has been evaluated in a porcine model of high dose metformin intoxication, which induces mitochondrial defects comparable to cyanide poisoning [22]. As expected, treated pigs exhibited reduced VO<sub>2</sub> and marked lactic acidosis, in spite of preserved systemic DO<sub>2</sub>. However, although VCO<sub>2</sub> decreased less than VO<sub>2</sub>, suggesting some anaerobic VCO<sub>2</sub>, no significant increase in Pv-aCO<sub>2</sub> gap was noted. In a human case report of massive metformin intoxication, Waldauf et al. also reported no elevation in Pv-aCO<sub>2</sub> gap despite major lactic acidosis and reduced aerobic VO<sub>2</sub>, as detected by increased SvO<sub>2</sub> [23]. Therefore, although data are very limited, cytopathic dysoxia related to impaired mitochondrial respiration appears not to widen the Pv-aCO<sub>2</sub> gap.

#### **The Pv-aCO<sub>2</sub> gap in sepsis**

Ongoing tissue dysoxia with persistent lactic acidosis is a hallmark of sepsis, and associated with a poor prognosis. Although a hyperdynamic circulation is characteristic of sepsis, many septic patients may have a cardiac output that is insufficient to meet metabolic demands, because of persistent hypovolemia or concomitant myocardial dysfunction. An increased Pv-aCO<sub>2</sub> gap has been reported in patients with lower cardiac output in sepsis, consistent with the ability of the Pv-aCO<sub>2</sub> gap to detect stagnant dysoxia, also in the context of sepsis [24]. In

such conditions, an increase in cardiac output correlates with a parallel decrease in Pv-aCO<sub>2</sub> gap [25]. Importantly, as reported by Vallee et al. [26], the Pv-aCO<sub>2</sub> gap is able to detect persistently low cardiac output even in patients with a normal SvO<sub>2</sub>. Such a high Pv-aCO<sub>2</sub> gap during the early resuscitation of septic shock has been correlated with more organ dysfunction and worse outcomes [27].

Many septic patients display persistent lactic acidosis in spite of an elevated cardiac output and normal or even increased SvO<sub>2</sub>. This implies that mechanisms unrelated to macrohemodynamics sustain tissue dysoxia in this setting, i.e., a loss of so-called hemodynamic coherence, with significant negative impact on outcome [28]. Impaired microcirculatory perfusion is indeed a prototypical perturbation in experimental [29] and human sepsis [30], which may impair tissue oxygenation. Such microcirculatory derangements result in tissue CO<sub>2</sub> accumulation, which can be tracked, for example, by sublingual capnometry, as shown by Creteur et al. [31]. Accordingly, in a prospective observational study including 75 patients with septic shock, Ospina-Tascon et al. found a significant correlation between Pv-aCO<sub>2</sub> gap and microcirculatory alterations. These were independent of systemic hemodynamic status and persisted even after correction for the Haldane effect [32], indicating that the Pv-aCO<sub>2</sub> gap may be a useful tool to assess impaired microcirculation in sepsis [33]. Furthermore, Creteur et al. reported that increasing cardiac output with dobutamine in patients with impaired microcirculation resulted in a decreased regional PCO<sub>2</sub> gap (sublingual and gastric mucosal) that was associated with a significant increase in well-perfused capillaries [31].

In summary, an elevated (>6 mmHg) Pv-aCO<sub>2</sub> gap in sepsis detects stagnant dysoxia, whether related to a low cardiac output or a derangement in microcirculatory blood flow, and this holds true even in the presence of a normal or elevated SvO<sub>2</sub>. As such, a high Pv-aCO<sub>2</sub> gap might prompt a trial to improve tissue blood flow by increasing cardiac output [34].

Finally, many septic patients with an elevated cardiac output exhibit a normal Pv-aCO<sub>2</sub> gap, resulting from elevated CO<sub>2</sub> washout by increased tissue blood flow. Many of these patients still display signs of ongoing dysoxia with lactic acidosis and organ dysfunction. Whether this pattern reflects cytopathic dysoxia or regional microcirculatory alterations not tracked by Pv-aCO<sub>2</sub> gap elevation remains to be established.

### Use of the Pv-aCO<sub>2</sub> gap as a prognostic tool

In sepsis, evidence exists that a Pv-aCO<sub>2</sub> gap >6 mmHg, even after normalization of blood lactate, is predictive of poor outcomes [35–37], which has been highlighted in a recent systematic review of 12 observational studies

[38]. Whether this holds true for a broader population of critically ill patients with circulatory shock has been questioned in a recent meta-analysis of 21 studies with a total of 2155 patients from medical, surgical and cardiovascular ICUs [37]. Overall, a high Pv-aCO<sub>2</sub> gap was associated with higher lactate levels, lower cardiac output and central venous oxygen saturation (ScvO<sub>2</sub>), and was significantly correlated with mortality. The latter was however restricted to medical and surgical patients, with no association found for cardiac surgery patients. Since the meta-analysis included only two studies in cardiac surgery, this negative result should be interpreted with caution. Three recent retrospective studies not included in the meta-analysis [39–41] indeed reported a negative impact of high postoperative Pv-aCO<sub>2</sub> gap on major complications and mortality after cardiac surgery, although with limited diagnostic performance [41].

Future studies are needed to refine the value of the Pv-aCO<sub>2</sub> gap as a prognostic biomarker in cardiac surgery patients, taking into account the low mortality (3.4%) in this population [42].

### Pitfalls in the interpretation of the Pv-aCO<sub>2</sub> gap



As already mentioned, several factors may influence the position of the PCO<sub>2</sub>-CCO<sub>2</sub> relationship by influencing the *k* factor of proportionality between both variables (see Fig. 2), which must be taken into account for a proper interpretation of the Pv-aCO<sub>2</sub> gap. These include the oxygen saturation of hemoglobin (Haldane effect), metabolic shifts of pH, temperature and hemoglobin concentration. In addition, it is essential to consider possible sources of errors in the measurement of PCO<sub>2</sub>, including contamination of the samples with fluid or air bubbles, and insufficient precision of the gas analyzer. When comparing successive determinations of Pv-aCO<sub>2</sub> gap, it is therefore recommended to consider only variations of at least ± 2 mmHg as real changes [43].

Two additional confounders in the interpretation of the Pv-aCO<sub>2</sub> gap require some discussion. The first is hyperoxia. It has been observed that, in patients with circulatory shock, ventilation at 100% inspired oxygen fraction (FiO<sub>2</sub>) for 5 min increased venous PCO<sub>2</sub>, and hence the Pv-aCO<sub>2</sub> gap, independent of changes in the hemodynamic status [44]. While this observation may be explained by a lower CO<sub>2</sub> affinity of hemoglobin due to elevated venous PO<sub>2</sub> (Haldane effect) [44], it may also reflect some impairment in microcirculatory blood flow, owing to the vasoconstrictive effects of hyperoxia [45]. The second confounder is acute hyperventilation with respiratory alkalosis. For example, as shown by Mallat et al. in 18 stable septic shock patients [46], an acute decrease in arterial PCO<sub>2</sub> from 44 to 34 mmHg produced by transient hyperventilation

(30 min) induced a significant increase in  $PCO_2$  gap (absolute 2.2 mmHg, relative + 48.5%). Possible mechanisms include, first, increased aerobic production of  $CO_2$  due to stimulated aerobic glycolysis under conditions of cellular alkalosis, and second, a reduction in microcirculatory blood flow due to the acute drop of  $CO_2$ . Thus, both acute hyperoxia and hypocapnia may be important confounders in the interpretation of an increased Pv-a $CO_2$  gap, which must be taken into account by the clinician.

**Conclusion**

The Pv-a $CO_2$  gap is a reliable indicator of impaired tissue perfusion, whether the result of a global reduction in cardiac output or to microcirculatory abnormalities, but it does not track tissue dysoxia, unless related to a stagnant mechanism. Being easily accessible and readily available, the Pv-a- $CO_2$  gap should be included in the integrated evaluation of the patient in circulatory shock. Several diagnostic algorithms incorporating Pv-a- $CO_2$  gradients have been proposed, such as those presented in Figs. 4



and 5. It remains to be established whether the Pva-CO<sub>2</sub> gap should be part of a resuscitation bundle protocol, and whether therapies aimed at normalizing an increased Pva-CO<sub>2</sub> gap could improve the dismal prognosis of circulatory shock.

#### Acknowledgements

None.

#### Authors' contributions

ZL performed the literature review drew the figures and drafted the manuscript. AS critically reviewed the manuscript. LL critically reviewed the manuscript. All authors read and approved the final manuscript.

#### Funding

The study and publication costs were funded by the intensive care unit research fund.

#### Availability of data and materials

Not applicable.

#### Declarations

#### Ethics approval and consent to participate

Not applicable.

#### Consent for publication

Not applicable.

#### Competing interests

All authors stated they have no conflicts of interest to declare.

#### Author details

<sup>1</sup>Service of Adult Intensive Care Medicine, Lausanne University Hospital, 1011 Lausanne, Switzerland. <sup>2</sup>Unit of Pathophysiology, Faculty of Biology and Medicine, University of Lausanne, 1011 Lausanne, Switzerland.

Published online: 31 August 2021

#### References

- Gavelli F, Teboul JL, Monnet X. How can CO<sub>2</sub>-derived indices guide resuscitation in critically ill patients? *J Thorac Dis*. 2019;11(Suppl 11):S1528–37.
- Geers C, Gros G. Carbon dioxide transport and carbonic anhydrase in blood and muscle. *Physiol Rev*. 2000;80:681–715.
- Douglas AR, Jones NL, Reed JW. Calculation of whole blood CO<sub>2</sub> content. *J Appl Physiol*. 1988;65:473–7.
- Dash RK, Bassingthwaite JB. Blood HbO<sub>2</sub> and HbCO<sub>2</sub> dissociation curves at varied O<sub>2</sub>, CO<sub>2</sub>, pH, 2,3-DPG and temperature levels. *Ann Biomed Eng*. 2004;32:1676–93.
- Dres M, Monnet X, Teboul JL. Hemodynamic management of cardiovascular failure by using PCO<sub>2</sub>(2) venous-arterial difference. *J Clin Monitor Comput*. 2012;26:367–74.
- van Beest PA, Lont MC, Holman ND, Loef B, Kuiper MA, Boerma EC. Central venous-arterial pCO<sub>2</sub>(2) difference as a tool in resuscitation of septic patients. *Intensive Care Med*. 2013;39:1034–9.
- Zhang H, Vincent JL. Arteriovenous differences in PCO<sub>2</sub> and pH are good indicators of critical hypoperfusion. *Am Rev Respir Dis*. 1993;148:867–71.
- Teboul JL, Mercat A, Lenique F, Berton C, Richard C. Value of the venous-arterial PCO<sub>2</sub> gradient to reflect the oxygen supply to demand in humans: effects of dobutamine. *Crit Care Med*. 1998;26:1007–10.
- Denault A, Guimond JG. Does measuring veno-arterial carbon dioxide difference compare to predicting a hockey game's final score? *Can J Anesthesia*. 2021;68:445–53.
- Hayes MA, Timmins AC, Yau EH, Palazzo M, Hinds CJ, Watson D. Elevation of systemic oxygen delivery in the treatment of critically ill patients. *N Engl J Med*. 1994;330:1717–22.
- Robin E, Futier E, Pires O, Fleyfel M, Tavernier B, Lebuffe G, et al. Central venous-to-arterial carbon dioxide difference as a prognostic tool in high-risk surgical patients. *Crit Care*. 2015;19:227.
- Monnet X, Julien F, Ait-Hamou N, Lequoy M, Gosset C, Jozwiak M, et al. Lactate and venoarterial carbon dioxide difference/arterial-venous oxygen difference ratio, but not central venous oxygen saturation, predict increase in oxygen consumption in fluid responders. *Crit Care Med*. 2013;41:1412–20.
- Ducrocq N, Kimmoun A, Levy B. Lactate or ScvO<sub>2</sub> as an endpoint in resuscitation of shock states? *Minerva Anesthesiol*. 2013;79:1049–58.
- Groeneveld AB. Interpreting the venous-arterial PCO<sub>2</sub> difference. *Crit Care Med*. 1998;26:979–80.
- Vallet B, Teboul JL, Cain S, Curtis S. Venous-arterial CO<sub>2</sub>(2) difference during regional ischemic or hypoxic hypoxia. *J Appl Physiol*. 2000;89:1317–21.
- Neviere R, Chagnon JL, Teboul JL, Vallet B, Wattel F. Small intestine intramucosal PCO<sub>2</sub>(2) and microvascular blood flow during hypoxic and ischemic hypoxia. *Crit Care Med*. 2002;30:379–84.
- Dubin A, Estenssoro E, Murias G, Pozo MO, Sottile JP, Baran M, et al. Intramucosal-arterial PCO<sub>2</sub> gradient does not reflect intestinal dysoxia in anemic hypoxia. *J Trauma*. 2004;57:1211–7.
- Ferrara G, Kanoore Edul VS, Martins E, Canales HS, Canullán C, Murias G, et al. Intestinal and sublingual microcirculation are more severely compromised in hemodilution than in hemorrhage. *J Appl Physiol*. 2016;120:1132–40.
- Liaudet L, Oddo M. Role of poly(adenosine diphosphate-ribose) polymerase 1 in septic peritonitis. *Curr Opin Crit Care*. 2003;9:152–8.
- Fink MP. Cytopathic hypoxia and sepsis: is mitochondrial dysfunction pathophysiologically important or just an epiphenomenon. *Pediatr Crit Care Med*. 2015;16:89–91.
- Mik EG, Balestra GM, Harms FA. Monitoring mitochondrial PO<sub>2</sub>: the next step. *Curr Opin Crit Care*. 2020;26:289–95.
- Andreis DT, Mallat J, Tettamanti M, Chiarla C, Giovannini I, Gatti S, et al. Increased ratio of P[v-a]CO<sub>2</sub> to C[a-v]O<sub>2</sub> without global hypoxia: the case of metformin-induced lactic acidosis. *Respir Physiol Neurobiol*. 2021;285:103586.
- Waldauf P, Jiroutkova K, Duska F. Using PCO<sub>2</sub> gap in the differential diagnosis of hyperlactatemia outside the context of sepsis: a physiological review and case series. *Crit Care Res Pract*. 2019;2019:5364503.
- Bakker J, Vincent JL, Gris P, Leon M, Coffernils M, Kahn RJ. Venous-arterial carbon dioxide gradient in human septic shock. *Chest*. 1992;101:509–15.
- Mecher CE, Rackow EC, Astiz ME, Weil MH. Venous hypercarbia associated with severe sepsis and systemic hypoperfusion. *Crit Care Med*. 1990;18:585–9.
- Vallee F, Vallet B, Mathe O, Parraguette J, Mari A, Silva S, et al. Central venous-to-arterial carbon dioxide difference: an additional target for goal-directed therapy in septic shock? *Intensive Care Med*. 2008;34:2218–25.
- Ospina-Tascon GA, Bautista-Rincon DF, Umana M, Tafur JD, Gutierrez A, Garcia AF, et al. Persistently high venous-to-arterial carbon dioxide differences during early resuscitation are associated with poor outcomes in septic shock. *Crit Care*. 2013;17:R294.
- De Backer D, Donadello K, Sakr Y, Ospina-Tascon G, Salgado D, Scolletta S, et al. Microcirculatory alterations in patients with severe sepsis: impact of time of assessment and relationship with outcome. *Crit Care Med*. 2013;41:791–9.
- Revelly JP, Liaudet L, Frascarolo P, Joseph JM, Martinet O, Markert M. Effects of norepinephrine on the distribution of intestinal blood flow and tissue adenosine triphosphate content in endotoxic shock. *Crit Care Med*. 2000;28:2500–6.
- De Backer D, Creteur J, Preiser JC, Dubois MJ, Vincent JL. Microvascular blood flow is altered in patients with sepsis. *Am J Respir Crit Care Med*. 2002;166:98–104.
- Creteur J, De Backer D, Sakr Y, Koch M, Vincent JL. Sublingual capnometry tracks microcirculatory changes in septic patients. *Intensive Care Med*. 2006;32:516–23.
- Ospina-Tascon GA, Umana M, Bermudez WF, Bautista-Rincon DF, Valencia JD, Madrinan HJ, et al. Can venous-to-arterial carbon dioxide differences

- reflect microcirculatory alterations in patients with septic shock? *Intensive Care Med.* 2016;42:211–21.
33. De Backer D. Is microcirculatory assessment ready for regular use in clinical practice? *Curr Opin Crit Care.* 2019;25:280–4.
  34. Teboul JL, Saugel B, Cecconi M, De Backer D, Hofer CK, Monnet X, et al. Less invasive hemodynamic monitoring in critically ill patients. *Intensive Care Med.* 2016;42:1350–9.
  35. Mallat J, Pepy F, Lemyze M, Gasan G, Vangrunderbeeck N, Tronchon L, et al. Central venous-to-arterial carbon dioxide partial pressure difference in early resuscitation from septic shock: a prospective observational study. *Eur J Anaesthesiol.* 2014;31:371–80.
  36. Vallet B, Pinsky MR, Cecconi M. Resuscitation of patients with septic shock: please “mind the gap!” *Intensive Care Med.* 2013;39:1653–5.
  37. Al Duhailib Z, Hegazy AF, Lalli R, Fiorini K, Priestap F, Iansavichene A, et al. The use of central venous to arterial carbon dioxide tension gap for outcome prediction in critically ill patients: a systematic review and meta-analysis. *Crit Care Med.* 2020;48:1855–61.
  38. Diaztagle Fernandez JJ, Rodriguez Murcia JC, Sprockel Diaz JJ. Venous-to-arterial carbon dioxide difference in the resuscitation of patients with severe sepsis and septic shock: a systematic review. *Med Intensiva.* 2017;41:401–10.
  39. Mukai A, Suehiro K, Kimura A, Funai Y, Matsuura T, Tanaka K, et al. Comparison of the venous-arterial CO<sub>2</sub> to arterial-venous O<sub>2</sub> content difference ratio with the venous-arterial CO<sub>2</sub> gradient for the predictability of adverse outcomes after cardiac surgery. *J Clin Monitor Comput.* 2020;34:41–53.
  40. Zante B, Reichenspurner H, Kubik M, Schefold JC, Kluge S. Increased admission central venous-arterial CO<sub>2</sub> difference predicts ICU-mortality in adult cardiac surgery patients. *Heart Lung.* 2019;48:421–7.
  41. Huette P, Beyls C, Mallat J, Martineau L, Besserve P, Haye G, et al. Central venous-to-arterial CO<sub>2</sub> difference is a poor tool to predict adverse outcomes after cardiac surgery: a retrospective study. *Can J Anaesth.* 2021;68:467–76.
  42. Mazzeffi M, Zivot J, Buchman T, Halkos M. In-hospital mortality after cardiac surgery: patient characteristics, timing, and association with postoperative length of intensive care unit and hospital stay. *Ann Thorac Surg.* 2014;97:1220–5.
  43. Mallat J, Lemyze M, Tronchon L, Vallet B, Thevenin D. Use of venous-to-arterial carbon dioxide tension difference to guide resuscitation therapy in septic shock. *World J Crit Care Med.* 2016;5:47–56.
  44. Saludes P, Proenca L, Gruartmoner G, Ensenat L, Perez-Madrigal A, Espinal C, et al. Central venous-to-arterial carbon dioxide difference and the effect of venous hyperoxia: a limiting factor, or an additional marker of severity in shock? *J Clin Monitor Comput.* 2017;31:1203–11.
  45. Orbegozo Cortes D, Puflea F, Donadello K, Taccone FS, Gottin L, Creteur J, et al. Normobaric hyperoxia alters the microcirculation in healthy volunteers. *Microvasc Res.* 2015;98:23–8.
  46. Mallat J, Mohammad U, Lemyze M, Meddour M, Jonard M, Pepy F, et al. Acute hyperventilation increases the central venous-to-arterial PCO<sub>2</sub> difference in stable septic shock patients. *Ann Intensive Care.* 2017;7:31.

### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.